Eosinophilic oesophagitis (EoE) is a chronic, immune and/or antigen-mediated, clinicopathological disease defined by symptoms of oesophageal dysfunction, oesophageal eosinophilic inflammation, and exclusion of other causes of oesophageal eosinophilia including GERD
Potential interactions between GERD and EoE include eosinophilia as a component of chronic inflammation in GERD, coexistence of GERD and EoE, EoE causing GERD and GERD causing EoE
A notable proportion (∼40%) of patients with clinical, endoscopic and histological features of EoE demonstrate a clinical and histological response to PPI therapy, those with so-called PPI-responsive oesophageal eosinophilia
Predictors of PPI response among patients with oesophageal eosinophilia and suspected EoE are presently lacking
On the basis of current clinical and translational research, PPI-responsive oesophageal eosinophilia more closely resembles EoE than GERD
Benefits of PPI therapy in EoE could be due to their ability to restore integrity of the oesophageal epithelium or direct anti-inflammatory effects
Over the past three decades, the detection of oesophageal mucosal eosinophils has transitioned from a biomarker of GERD to a diagnostic criterion for eosinophilic oesophagitis (EoE). In GERD, oesophageal eosinophils are considered part of the chronic inflammatory response to acid reflux, whereas the marked eosinophilia in EoE is viewed as a central feature of the immune response to ingested food and/or environmental antigen stimulation. Descriptions of a considerable subset of patients with symptomatic, endoscopic and histological findings of EoE that resolve with PPI therapy has led to confusion and controversy regarding the distinction of EoE from GERD. Study findings indicate that PPI-responsive oesophageal eosinophilia (PPI-REE) more closely resembles EoE than GERD, both from a clinical and immunological aspect. Although responsiveness to PPI therapy should not be utilized to exclude EoE, PPI therapy is effective at reducing oesophageal eosinophilia in ∼40% of patients, and PPI therapy is both a safe and practical initial step in the management of patients with oesophageal eosinophilia. Ongoing studies elucidating the mechanism behind PPI-REE will improve our understanding and management of EoE. In this Review, the mechanisms and evidence that underlie the controversy in the distinction between GERD and EoE are evaluated.
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Dellon, E. S. et al. ACG clinical guideline: evidenced based approach to the diagnosis and management of esophageal eosinophilia and eosinophilic esophagitis (EoE). Am. J. Gastroenterol. 108, 679–692 (2013).
Liacouras, C. A. et al. Eosinophilic esophagitis: updated consensus recommendations for children and adults. J. Allergy Clin. Immunol. 128, 3–20 (2011).
Ngo, P., Furuta, G. T., Antonioli, D. A. & Fox, V. L. Eosinophils in the esophagus—peptic or allergic eosinophilic esophagitis? Case series of three patients with esophageal eosinophilia. Am. J. Gastroenterol. 101, 1666–1670 (2006).
Fass, R. & Gasiorowska, A. Refractory GERD: what is it? Curr. Gastroenterol. Rep. 10, 252–257 (2008).
Rodrigo, S. et al. High intraepithelial eosinophil counts in esophageal squamous epithelium are not specific for eosinophilic esophagitis in adults. Am. J. Gastroenterol. 103, 435–442 (2008).
Peery, A. F. et al. Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology 143, 1179–1187.e1–e3 (2012).
Winter, H. S. et al. Intraepithelial eosinophils: a new diagnostic criterion for reflux esophagitis. Gastroenterology 83, 818–823 (1982).
Brown, L. F., Goldman, H. & Antonioli, D. A. Intraepithelial eosinophils in endoscopic biopsies of adults with reflux esophagitis. Am. J. Surg. Pathol. 8, 899–905 (1984).
Odze, R. D. Pathology of eosinophilic esophagitis: what the clinician needs to know. Am. J. Gastroenterol. 104, 485–490 (2009).
Cheng, E., Souza, R. F. & Spechler, S. J. Eosinophilic esophagitis: interactions with gastroesophageal reflux disease. Gastroenterol. Clin. North Am. 43, 243–256 (2014).
Attwood, S. E., Smyrk, T. C., Demeester, T. R. & Jones, J. B. Esophageal eosinophilia with dysphagia. A distinct clinicopathologic syndrome. Dig. Dis. Sci. 38, 109–116 (1993).
Straumann, A., Spichtin, H. P., Bernoulli, R., Loosli, J. & Vogtlin, J. Idiopathic eosinophilic esophagitis: a frequently overlooked disease with typical clinical aspects and discrete endoscopic findings [German]. Schweiz. Med. Wochenschr. 124, 1419–1429 (1994).
Steiner, S. J., Gupta, S. K., Croffie, J. M. & Fitzgerald, J. F. Correlation between number of eosinophils and reflux index on same day esophageal biopsy and 24 hour esophageal pH monitoring. Am. J. Gastroenterol. 99, 801–805 (2004).
Johnson, L. F. & Demeester, T. R. Twenty-four-hour pH monitoring of the distal esophagus. A quantitative measure of gastroesophageal reflux. Am. J. Gastroenterol. 62, 325–332 (1974).
Pandolfino, J. E. & Vela, M. F. Esophageal-reflux monitoring. Gastrointest Endosc 69, 917–930.e1 (2009).
Ruchelli, E., Wenner, W., Voytek, T., Brown, K. & Liacouras, C. Severity of esophageal eosinophilia predicts response to conventional gastroesophageal reflux therapy. Pediatr. Dev. Pathol. 2, 15–18 (1999).
Kelly, K. J. et al. Eosinophilic esophagitis attributed to gastroesophageal reflux: improvement with an amino acid-based formula. Gastroenterology 109, 1503–1512 (1995).
Collins, M. H. Histopathologic features of eosinophilic esophagitis. Gastrointest. Endosc. Clin. N. Am. 18, 59–71 (2008).
Antonioli, D. A. & Furuta, G. T. Allergic eosinophilic esophagitis: a primer for pathologists. Semin. Diagn. Pathol. 22, 266–272 (2005).
Hirano, I. Eosinophilic esophagitis and gastroesophageal reflux disease: there and back again. Clin. Gastroenterol. Hepatol. 9, 99–101 (2011).
Kim, H. P., Vance, R. B., Shaheen, N. J. & Dellon, E. S. The prevalence and diagnostic utility of endoscopic features of eosinophilic esophagitis: a meta-analysis. Clin. Gastroenterol. Hepatol. 10, 988–996.e5 (2012).
Park, H. An overview of eosinophilic esophagitis. Gut Liver 8, 590–597 (2014).
Hirano, I. et al. Endoscopic assessment of the oesophageal features of eosinophilic oesophagitis: validation of a novel classification and grading system. Gut 62, 489–495 (2013).
Dellon, E. S. et al. Clinical, endoscopic, and histologic findings distinguish eosinophilic esophagitis from gastroesophageal reflux disease. Clin. Gastroenterol. Hepatol. 7, 1305–1313 (2009).
Veerappan, G. R. et al. Prevalence of eosinophilic esophagitis in an adult population undergoing upper endoscopy: a prospective study. Clin. Gastroenterol. Hepatol. 7, 420–426 (2009).
Aceves, S. S., Newbury, R. O., Dohil, M. A., Bastian, J. F. & Dohil, R. A symptom scoring tool for identifying pediatric patients with eosinophilic esophagitis and correlating symptoms with inflammation. Ann. Allergy Asthma Immunol. 103, 401–406 (2009).
Liacouras, C. A., Spergel, J. & Gober, L. M. Eosinophilic esophagitis: clinical presentation in children. Gastroenterol. Clin. North Am. 43, 219–229 (2014).
Liacouras, C. A. et al. Eosinophilic esophagitis: a 10-year experience in 381 children. Clin. Gastroenterol. Hepatol 3, 1198–1206 (2005).
Furuta, G. T. et al. Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment. Gastroenterology 133, 1342–1363 (2007).
Hirano, I. Role of advanced diagnostics for eosinophilic esophagitis. Dig. Dis. 32, 78–83 (2014).
Hirano, I., Richter, J. E. & Practice Parameters Committee of the American College of Gastroenterology. ACG practice guidelines: esophageal reflux testing. Am. J. Gastroenterol. 102, 668–685 (2007).
Spechler, S. J., Genta, R. M. & Souza, R. F. Thoughts on the complex relationship between gastroesophageal reflux disease and eosinophilic esophagitis. Am. J. Gastroenterol. 102, 1301–1306 (2007).
Barthel, S. R., Annis, D. S., Mosher, D. F. & Johansson, M. W. Differential engagement of modules 1 and 4 of vascular cell adhesion molecule-1 (CD106) by integrins α4β1 (CD49d/29) and αMβ2 (CD11b/18) of eosinophils. J. Biol. Chem. 281, 32175–32187 (2006).
Cheng, L. et al. Acid-induced release of platelet-activating factor by human esophageal mucosa induces inflammatory mediators in circular smooth muscle. J. Pharmacol. Exp. Ther. 319, 117–126 (2006).
Lampinen, M., Rak, S. & Venge, P. The role of interleukin-5, interleukin-8 and RANTES in the chemotactic attraction of eosinophils to the allergic lung. Clin. Exp. Allergy 29, 314–322 (1999).
Ma, J. et al. HCl-induced and ATP-dependent upregulation of TRPV1 receptor expression and cytokine production by human esophageal epithelial cells. Am. J. Physiol. Gastrointest. Liver Physiol. 303, G635–G645 (2012).
Rafiee, P. et al. Human esophageal microvascular endothelial cells respond to acidic pH stress by PI3K/AKT and p38 MAPK-regulated induction of Hsp70 and Hsp27. Am. J. Physiol. Cell Physiol. 291, C931–C945 (2006).
Souza, R. F. et al. Gastroesophageal reflux might cause esophagitis through a cytokine-mediated mechanism rather than caustic acid injury. Gastroenterology 137, 1776–1784 (2009).
Blanchard, C. et al. Eotaxin-3 and a uniquely conserved gene-expression profile in eosinophilic esophagitis. J. Clin. Invest. 116, 536–547 (2006).
Konikoff, M. R. et al. Potential of blood eosinophils, eosinophil-derived neurotoxin, and eotaxin-3 as biomarkers of eosinophilic esophagitis. Clin. Gastroenterol. Hepatol. 4, 1328–1336 (2006).
Shaheen, N. & Provenzale, D. The epidemiology of gastroesophageal reflux disease. Am. J. Med. Sci. 326, 264–273 (2003).
Molina-Infante, J., Katzka, D. A. & Gisbert, J. P. Review article: proton pump inhibitor therapy for suspected eosinophilic oesophagitis. Aliment. Pharmacol. Ther. 37, 1157–1164 (2013).
Cheng, L. et al. Hydrogen peroxide reduces lower esophageal sphincter tone in human esophagitis. Gastroenterology 129, 1675–1685 (2005).
Farre, R., Auli, M., Lecea, B., Martinez, E. & Clave, P. Pharmacologic characterization of intrinsic mechanisms controlling tone and relaxation of porcine lower esophageal sphincter. J. Pharmacol. Exp. Ther. 316, 1238–1248 (2006).
Cao, W. et al. Proinflammatory cytokines alter/reduce esophageal circular muscle contraction in experimental cat esophagitis. Am. J. Physiol. Gastrointest. Liver Physiol. 287, G1131–G1139 (2004).
Tobey, N. A., Carson, J. L., Alkiek, R. A. & Orlando, R. C. Dilated intercellular spaces: a morphological feature of acid reflux—damaged human esophageal epithelium. Gastroenterology 111, 1200–1205 (1996).
Ravelli, A. et al. Dilated intercellular spaces in eosinophilic esophagitis. J. Pediatr. Gastroenterol. Nutr. 59, 589–593 (2014).
Kwiatek, M. A. et al. Mechanical properties of the esophagus in eosinophilic esophagitis. Gastroenterology 140, 82–90 (2011).
Lin, Z. et al. Functional luminal imaging probe topography: an improved method for characterizing esophageal distensibility in eosinophilic esophagitis. Therap. Adv. Gastroenterol. 6, 97–107 (2013).
Calabrese, C. et al. Dilated intercellular spaces as a marker of oesophageal damage: comparative results in gastro-oesophageal reflux disease with or without bile reflux. Aliment. Pharmacol. Ther. 18, 525–532 (2003).
Ravelli, A. M. et al. Dilated intercellular spaces: a major morphological feature of esophagitis. J. Pediatr. Gastroenterol. Nutr. 42, 510–515 (2006).
Wechsler, J. B. & Bryce, P. J. Allergic mechanisms in eosinophilic esophagitis. Gastroenterol. Clin. North Am. 43, 281–296 (2014).
Noti, M. et al. Thymic stromal lymphopoietin-elicited basophil responses promote eosinophilic esophagitis. Nat. Med. 19, 1005–1013 (2013).
Dellon, E. S. et al. Clinical and endoscopic characteristics do not reliably differentiate PPI-responsive esophageal eosinophilia and eosinophilic esophagitis in patients undergoing upper endoscopy: a prospective cohort study. Am. J. Gastroenterol. 108, 1854–1860 (2013).
Sayej, W. N., Patel, R., Baker, R. D., Tron, E. & Baker, S. S. Treatment with high-dose proton pump inhibitors helps distinguish eosinophilic esophagitis from noneosinophilic esophagitis. J. Pediatr. Gastroenterol. Nutr. 49, 393–399 (2009).
Peterson, K. A. et al. Comparison of esomeprazole to aerosolized, swallowed fluticasone for eosinophilic esophagitis. Dig. Dis. Sci. 55, 1313–1319 (2010).
Dranove, J. E., Horn, D. S., Davis, M. A., Kernek, K. M. & Gupta, S. K. Predictors of response to proton pump inhibitor therapy among children with significant esophageal eosinophilia. J. Pediatr. 154, 96–100 (2009).
Francis, D. L. et al. Results of ambulatory pH monitoring do not reliably predict response to therapy in patients with eosinophilic oesophagitis. Aliment. Pharmacol. Ther. 35, 300–307 (2012).
Moawad, F. J. et al. Randomized controlled trial comparing aerosolized swallowed fluticasone to esomeprazole for esophageal eosinophilia. Am. J. Gastroenterol. 108, 366–372 (2013).
Molina-Infante, J. et al. Esophageal eosinophilic infiltration responds to proton pump inhibition in most adults. Clin. Gastroenterol. Hepatol. 9, 110–117 (2011).
Moawad, F. J. et al. Eosinophilic oesophagitis and proton pump inhibitor-responsive oesophageal eosinophilia have similar clinical, endoscopic and histological findings. Aliment. Pharmacol. Ther. 39, 603–608 (2014).
Krarup, A. L. et al. Acid hypersensitivity in patients with eosinophilic oesophagitis. Scand. J. Gastroenterol. 45, 273–281 (2010).
Tobey, N. A. et al. Dilated intercellular spaces and shunt permeability in nonerosive acid-damaged esophageal epithelium. Am. J. Gastroenterol. 99, 13–22 (2004).
van Rhijn, B. D. et al. Proton pump inhibitors partially restore mucosal integrity in patients with proton pump inhibitor-responsive esophageal eosinophilia but not eosinophilic esophagitis. Clin. Gastroenterol. Hepatol. 12, 1815–1823.e2 (2014).
Straumann, A., Bauer, M., Fischer, B., Blaser, K. & Simon, H. U. Idiopathic eosinophilic esophagitis is associated with a TH2-type allergic inflammatory response. J. Allergy Clin. Immunol. 108, 954–961 (2001).
Zhang, X. et al. Omeprazole blocks STAT6 binding to the eotaxin-3 promoter in eosinophilic esophagitis cells. PLoS ONE 7, e50037 (2012).
Lapenna, D., de Gioia, S., Ciofani, G., Festi, D. & Cuccurullo, F. Antioxidant properties of omeprazole. FEBS Lett. 382, 189–192 (1996).
Kedika, R. R., Souza, R. F. & Spechler, S. J. Potential anti-inflammatory effects of proton pump inhibitors: a review and discussion of the clinical implications. Dig. Dis. Sci. 54, 2312–2317 (2009).
Wandall, J. H. Effects of omeprazole on neutrophil chemotaxis, super oxide production, degranulation, and translocation of cytochrome b-245. Gut 33, 617–621 (1992).
Dohil, R., Newbury, R. O. & Aceves, S. Transient PPI responsive esophageal eosinophilia may be a clinical sub-phenotype of pediatric eosinophilic esophagitis. Dig. Dis. Sci. 57, 1413–1419 (2012).
Merwat, S. N. & Spechler, S. J. Might the use of acid-suppressive medications predispose to the development of eosinophilic esophagitis? Am. J. Gastroenterol. 104, 1897–1902 (2009).
Dellon, E. S. et al. Markers of eosinophilic inflammation for diagnosis of eosinophilic esophagitis and proton pump inhibitor-responsive esophageal eosinophilia: a prospective study. Clin. Gastroenterol. Hepatol. 12, 2015–2022 (2014).
Molina-Infante, J. et al. Proton pump inhibitor-responsive oesophageal eosinophilia correlates with downregulation of eotaxin-3 and Th2 cytokines overexpression. Aliment. Pharmacol. Ther. 40, 955–965 (2014).
Wen, T. et al. Transcriptome analysis of proton pump inhibitor-responsive esophageal eosinophilia reveals proton pump inhibitor-reversible allergic inflammation. J. Allergy Clin. Immunol. 135, 187–197 (2015).
Hirano, I. Editorial: Should patients with suspected eosinophilic esophagitis undergo a therapeutic trial of proton pump inhibition? Am. J. Gastroenterol. 108, 373–375 (2013).
Dellon, E. S., Farrell, T. M., Bozymski, E. M. & Shaheen, N. J. Diagnosis of eosinophilic esophagitis after fundoplication for 'refractory reflux': implications for preoperative evaluation. Dis. Esophagus 23, 191–195 (2010).
The authors acknowledge research funding support from the NIH for the Consortium of Eosinophilic Gastrointestinal disease Researchers (NIH U54 AI117804, which is part of the Rare Disease Clinical Research Network, an initiative of the Office of Rare Diseases Research, NCATS, and is funded through collaboration between NIAID, NIDDK, and NCATS) and an American Society of Gastrointestinal Endoscopy Research Award.
I.H. has acted as a consultant for Meritage pharma, Receptos pharma and Regeneron, these consultant roles are not relevant to the subject matter of the article under consideration. L.K. declares no competing interests.
About this article
Cite this article
Kia, L., Hirano, I. Distinguishing GERD from eosinophilic oesophagitis: concepts and controversies. Nat Rev Gastroenterol Hepatol 12, 379–386 (2015). https://doi.org/10.1038/nrgastro.2015.75
Seminars in Immunopathology (2021)
Low Prevalence of Extraesophageal Gastrointestinal Pathology in Patients with Eosinophilic Esophagitis
Digestive Diseases and Sciences (2021)
Obesity and hiatal hernia may be non-allergic risk factors for esophageal eosinophilia in Japanese adults
Clinical Reviews in Allergy & Immunology (2019)
Current Treatment Options in Gastroenterology (2018)